Necessity of amoxicillin clavulanic acid in addition to prednisolone in mild-to-moderate COPD exacerbations

Marjolein Brusse-Keizer,1 Paul VanderValk,1 Ron Hendrix,2,3 Huib Kerstjens,4 Job van der Palen1,5

ABSTRACT

Background: The effectiveness of antibiotics in chronic obstructive pulmonary disease (COPD) exacerbations is still a matter of debate, especially in outpatient settings with an intermediate probability of bacterial infection.

Methods: In this study, 35 COPD outpatients diagnosed by their chest physician with moderately severe COPD exacerbation, but without pneumonia, were randomised in a double blind, placebo-controlled study. Patients had one or two of the following characteristics: a positive Gram’s stain of the sputum, 2 or more exacerbations in the previous year, a decrease in lung function of ≥200 mL and ≥12%. Patients received amoxicillin clavulanic acid (500/125 mg three times daily) or placebo for 7 days, always combined with a course of prednisolone (30 mg/day) for 7 days. Primary outcome was duration of the exacerbation. Additionally, we measured severity of the exacerbation, health-related quality of life, sputum parameters, number of relapses within 28 days and the number of re-exacerbations within 4 months after the study.

Results: There was no difference observed in time to resolution of the exacerbation between the two groups (HR=1.12; 95% CI 0.5 to 2.3; p=0.77)), nor in any other treatment parameter.

Conclusions: We detected no evidence for the effectiveness of addition of antibiotics to prednisolone for COPD exacerbations of moderate severity and with intermediate probability of bacterial infection in this underpowered study. More placebo-controlled studies are needed to properly define subgroups of COPD outpatients in which antibiotics are of additional value.

Trials registration number: clinical trial registered with http://www.trialregister.nl/(NTR351).

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is characterised by acute exacerbations (AECOPD) that are associated with substantial morbidity and mortality.1-3 Management of AECOPD includes oral corticosteroids often combined with broad spectrum antibiotics to treat a presumed bacterial infection.4 Some antibiotics, especially the macrolides, are also sometimes provided prophylactically for longer term use due to their anti-inflammatory, immunomodulatory or antiviral effects.5 A short course of broad spectrum antibiotics during AECOPD is, however, mainly used for their antibacterial effect. Their use remains controversial due to several reasons. First only approximately one-third of AECOPD are due to bacterial infections.6 Second, given the existence of bacterial infections, the treatment is empirical since culture and resistance results usually take 1 week to become available. Third, growing resistance against antibacterial agents is an additional reason to be reluctant to give a prescription of antibiotics.7 8 Finally and perhaps most importantly, there is no definitive evidence that antibiotics offer benefits in outpatients with mild-to-moderate AECOPD.9 10

The latest international guidelines recommend antibiotics to patients with AECOPD who have three cardinal symptoms (increase in dyspnoea, sputum volume and sputum purulence); patients who have two of the cardinal symptoms, if increased purulence of sputum is one of the two symptoms; or to patients who require mechanical ventilation (invasive or non-invasive).11 These criteria originated from the study by Anthonisen et al12 which showed only a marginal benefit from antibiotics in a subgroup of patients. They divided AECOPD into three categories and concluded that in case of the presence of all three of the above...
mentioned criteria (type I) the cause of the AECOPD is probably bacterial and is more likely to have a favourable outcome with antibiotics.12

Unfortunately, most placebo-controlled antibiotics trials, on which these guidelines are based, have important limitations and are difficult to compare because of different definitions of COPD and AECOPD, and different end points that have been used.13 14 Furthermore, these trials were conducted several decades ago, before systemic steroids were widely introduced for the treatment of AECOPD.15–18

Even in the recently published study by Lior et al.,19 in which a beneficial effect with amoxicillin/clavulanic acid compared to placebo was observed, only 17% of the patients were treated with systemic steroids.20 Furthermore, as stated in the Cochrane Review of Vollenweider et al.,21 reported that an Anthonisen type I AECOPD did not predict a bacterial origin of an outpatient’s AECOPD and that sputum purulence was poorly associated with bacterial infection. This study did, however, found that the combination of a positive Gram’s stain of sputum, a clinically relevant lung function decrease and >two AECOPDs in the previous year were 67% predictive for a bacterial origin of the AECOPD and therefore, postulated to warrant antibiotic treatment. The absence of all three characteristics gave a negative predictive value of 100% for a non-bacterial origin, suggesting to abstain from administering the antibiotics.21 This leaves patients with one or two of these characteristics. Therefore, in the current double-blind, randomised, placebo-controlled study, we evaluated the effect of an antibiotic on the duration and severity of AECOPDs in outpatients with one or two of the three mentioned characteristics.

METHODS

Patients

Patients with COPD were recruited from May 2005 till January 2007 from the outpatient pulmonary clinic of Medisch Spectrum Twente, Enschede, The Netherlands. Patients had to meet the following criteria: (1) a diagnosis of COPD according to the GOLD-criteria; (2) current or ex-smoker; (3) age 40–80 years; (4) presenting at the outpatient clinic with an AECOPD, defined as an acute negative change in dyspnoea and/or sputum volume and/or colour of sputum (yellowish or greenish) and/or cough, which warrants additional treatment with prednisolone with or without antibiotics by a physician; (5) no requirement of hospitalisation; (6) no pneumonia based on chest X-ray;22 (7) ability to produce a spontaneous sputum sample; (8) presenting with one or two of the clinical characteristics: a positive Gram’s stain of sputum, a clinically relevant lung function decrease (decrease in FEV₁ of ≥200 mL and ≥12% from baseline), or >2 AECOPDs in the previous year;21 (9) no AECOPD or use of antibiotics or prednisolone 4 weeks prior to enrolment, except for low-dose prednisolone (≤5 mg) as maintenance therapy; (10) no disease that influences bronchial symptoms or lung function; (11) no maintenance therapy with antibiotics; (12) no known hypersensitivity to amoxicillin/ clavulanic acid; (13) no medical condition with low survival or serious psychiatric morbidity; (14) no uncontrolled diabetes mellitus; (15) no need for domiciliary oxygen therapy; and (16) no participation in another clinical trial.

The hospital’s medical ethics committee approved the study. All patients provided written informed consent.

Study design

This study was a randomised, double-blind, placebo-controlled study. Eligible patients were randomly assigned in a one-to-one ratio to either the intervention or control group based on a computer generated randomisation list. The hospital pharmacy provided both amoxicillin/clavulanic acid and placebo in identical containers with identical capsules. Based on the randomisation list, the hospital pharmacy sequentially numbered the containers with both amoxicillin/clavulanic acid and placebo. This list was kept in a safe at the hospital pharmacy throughout the course of the study. Patients received these numbered containers in sequence of randomisation, which was recorded on a medication distribution list.

Patients in both groups received oral prednisolone, 30 mg/day for 7 days. Patients in the intervention group additionally received oral amoxicillin/clavulanic acid (Augmentin) 500/125 mg three times daily for 7 days, while control patients received a matching placebo. The choice for this amoxicillin/clavulanic acid is based on the negligible prevalence of organisms resistance in our region (less than 5%). All patients continued their prescribed inhaled regimen. Patients were followed for 28 days for the primary outcome and for 4 months to detect new AECOPDs.

Outcome measures

The primary outcome was the duration of the AECOPD. Start of the AECOPD was defined as the day the patient presented with an AECOPD at the outpatient clinic. The end day of the AECOPD was based on a symptom diary, which patients completed daily.23 In this diary, patients reported whether their major symptoms and minor symptoms, according to Anthonisen et al.24 (table 1), were beyond normal. At inclusion all patients received a ‘what is normal’ card on which their individual levels of major symptoms in stable health state were recorded. This card was used as a reference for the diary. When patients experienced no increase in severity of any symptoms listed in the diary, they could tick ‘no change in symptoms’. In all other cases, they had to report on all the symptoms in the diary - whether the level of each symptom was normal, whether there was a small increase or an evident increase in severity compared to their stable state.

The last day of the AECOPD was defined as the first day of: (1) three consecutive days when the patient had...
tive culture were made. Infection was de-

Table 1 Scoring of COPD AECOPD symptoms

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Normal</th>
<th>Small increase</th>
<th>Evident increase/change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Sputum production</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Sputum colour</td>
<td>0</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Minor symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>0</td>
<td>0.5</td>
<td>1</td>
</tr>
<tr>
<td>Wheeze</td>
<td>0</td>
<td>0.5</td>
<td>1</td>
</tr>
<tr>
<td>Running nose</td>
<td>0</td>
<td>0.5</td>
<td>1</td>
</tr>
<tr>
<td>Sore throat</td>
<td>0</td>
<td>0.5</td>
<td>1</td>
</tr>
<tr>
<td>Fever</td>
<td>0</td>
<td>1†</td>
<td></td>
</tr>
</tbody>
</table>

*Sputum colour: normal=0; different from normal=2.†Fever (>38.5°C); no=0; yes=1.

AECOPD, acute exacerbations in COPD; COPD, chronic obstructive pulmonary disease.

returned to his normal health state; or (2) seven con-
secutive days in which patients only reported a minor in-
symptoms compared to baseline, without fever or changed sputum colour.

Secondary outcome measures were the severity of the
AECOPD, number of relapses of AECOPDs within
28 days, number of AECOPDs within 4 months, lung
function parameters, sputum parameters and HRQoL.

Severity of the AECOPD was based on the symptom
scores in the diary and was calculated as predefined in
the protocol. On each day of the AECOPD, a severity
score was calculated (table 1). Adding the symptom
scores resulted in a daily score ranging from 0 to 11
points. A mean severity score per AECOPD day was cal-
culated by dividing the sum scores of each AECOPD day
by the number of days the AECOPD lasted.23

A relapse was defined as an AECOPD that resolved fol-
owing the blinded treatment but re-occurred within
28 days of the treated AECOPD. The number of
AECOPDs within 4 months was estimated by counting
the number of courses of prednisolone and antibiotics
prescribed for lung-associated illness, based on data from
pharmacy records. In our region this provides a very
accurate coverage of consumption. Pharmacy data were
similarly used to determine the number of AECOPDs in
the year prior to the start of the study.

At the start of the study and after 28 days, lung func-
tion was measured. Spontaneous sputum samples were
collected and sputum colour was determined according
to the Stockley protocol nine-point colour chart
(Bronkotest, Heredilab Inc, Salt Lake City, Utah,
USA). Sputum with a colour value ≤2 was defined as
‘mucoid’ and sputum colour ≥3 was defined as ‘puru-

The level of PCT was measured in blood samples that
were derived at the start. PCT levels were assessed with an
automated sandwich immunoassay using a time-resolved
amplified cryptate emission technology (TRACE; Kryptor
PCT; Brahms AG; Hennigsdorf, Germany). The PCT
assays has a detection limit of 0.02 ng/mL and a
functional assay sensitivity of 0.06 ng/mL. PCT levels
were also divided based on the cut-off levels determined
by Stolz et al26 that were set at >0.1 µg/L, between
0.1–0.25 µg/L and >0.25 µg/L.

HRQoL was measured by means of the Chronic
Respiratory Questionnaire (CRQ).27 Health status was mea-
sured with the Clinical COPD Questionnaire (CCQ).28 29

Statistical analysis
With an expected mean duration of an exacerbation of
approximately 15 days, a difference of 3 days in the dur-
ation of AECOPD between the treatment groups was
defined prior to the study as clinically relevant. With a
SD of 4 days, power of 80%, and α of 5%, 58 patients
were required to detect this difference.

The relation between treatment and the duration of the
AECOPD was analysed by Cox-regression analysis. To iden-
tify continuous variables that were different between treat-
ment group, t tests or Mann-Whitney U test for the
normally and not normally distributed variables were per-
formed. Between-group comparisons of categorical vari-
able were performed by χ² tests or Fisher’s exact tests, as
appropriate. The a priori list of potential confounding
variables is displayed in table 2. Only variables different by
treatment group (p≤0.20) were tested for an association
with duration of the AECOPD. Variables associated with
duration of the AECOPD with p≤0.20 were considered as
potential confounders in the relation between treatment
duration and of the AECOPD, and were entered into the
multivariate Cox-regression analysis. Time to resolution
was displayed as a Kaplan-Meier graph.

RESULTS
Of 63 potentially eligible patients with an AECOPD, 35
patients were randomised; 18 received amoxicillin/
clavulanic acid and 17 placebo (figure 1). All patients completed the treatment and follow-up. Baseline characteristics are displayed in table 2. At baseline, FEV₁ (in litres and as % predicted), sputum culture, colour and purulence showed to be potential confounders since these were associated to treatment with p<0.20. Therefore, these variables were tested for association with the duration of treatment (also p<0.20). Since this was not the case for any variable, no adjustment of treatment effect on the duration of the AECOPD was necessary.

In 15 patients (83%) in the intervention group, the AECOPD resolved within 28 days compared to 14 patients (82%) that received placebo (see table 3). Since not all of the AECOPDs resolved within 28 days, we were not able to calculate the mean duration of the AECOPD. Therefore, we calculated the median time till resolution which was 7 days (95% CI 2.8 to 11.2) in the amoxicillin group compared to 10 days (95% CI 3.3 to 16.7) in the placebo group (p=0.75).

The crude HR of time to resolution of the AECOPD in patients in the intervention group was 1.12 (95% CI

### Table 2  Baseline characteristics of the two treatment groups

<table>
<thead>
<tr>
<th></th>
<th>Amoxicillin/clavulanic acid</th>
<th>Placebo</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (number of men (%))</td>
<td>N=18</td>
<td>N=17</td>
<td></td>
</tr>
<tr>
<td>Smoking status (number (%))</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ex-smokers</td>
<td>14 (78)</td>
<td>11 (65)</td>
<td>0.42</td>
</tr>
<tr>
<td>Current smokers</td>
<td>4 (22)</td>
<td>6 (35)</td>
<td></td>
</tr>
<tr>
<td>Age (median (range))</td>
<td>68 (54–74)</td>
<td>65 (47–76)</td>
<td>0.38</td>
</tr>
<tr>
<td>Lung function postbronchodilatation at inclusion (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV₁ in litres</td>
<td>1.24 (0.44)</td>
<td>1.53 (0.54)</td>
<td>0.06</td>
</tr>
<tr>
<td>FEV₁% predicted</td>
<td>44.7 (15.4)</td>
<td>52.2 (15.1)</td>
<td>0.16</td>
</tr>
<tr>
<td>FEV₁/VC %</td>
<td>38.3 (13.0)</td>
<td>42.9 (11.2)</td>
<td>0.27</td>
</tr>
<tr>
<td>Positive Gram’s stain (number (%))</td>
<td>15 (83)</td>
<td>15 (88)</td>
<td>1.00</td>
</tr>
<tr>
<td>Sputum culture at inclusion (Number (%))</td>
<td>3 (17)</td>
<td>5 (29)</td>
<td>0.18</td>
</tr>
<tr>
<td>No colonisation nor infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colonisation</td>
<td>2 (11)</td>
<td>5 (29)</td>
<td></td>
</tr>
<tr>
<td>Infection</td>
<td>13 (72)</td>
<td>7 (41)</td>
<td></td>
</tr>
<tr>
<td>AECOPDs in the previous year (number (%))</td>
<td>7 (39)</td>
<td>8 (47)</td>
<td>0.63</td>
</tr>
<tr>
<td>&lt;2 AECOPDs</td>
<td>11 (61)</td>
<td>9 (53)</td>
<td></td>
</tr>
<tr>
<td>≥2 AECOPDs</td>
<td>2 (11)</td>
<td>2 (12)</td>
<td>1.00</td>
</tr>
<tr>
<td>Lung function decline of ≥200 mL and ≥12% at start of AECOPD compared to baseline* (number (%))</td>
<td>4.4 (1.2)</td>
<td>3.4 (1.1)</td>
<td>0.02</td>
</tr>
<tr>
<td>Sputum colour score† (SD)</td>
<td>17 (94)</td>
<td>13 (77)</td>
<td>0.17</td>
</tr>
<tr>
<td>Purulent sputum (number (%))</td>
<td>15 (83)</td>
<td>12 (71)</td>
<td></td>
</tr>
<tr>
<td>Type of AECOPD according to Anthonisen (number (%))</td>
<td>3 (17)</td>
<td>5 (29)</td>
<td>0.44</td>
</tr>
<tr>
<td>Type I (3 major symptoms)</td>
<td>15 (83)</td>
<td>12 (71)</td>
<td></td>
</tr>
<tr>
<td>Type II (2 major symptoms)</td>
<td>3 (17)</td>
<td>5 (29)</td>
<td></td>
</tr>
<tr>
<td>Type III (1 major+1 minor symptom)</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Procalcitonin level (µg/L) (median (range))</td>
<td>0.06 (0.03–0.22)</td>
<td>0.06 (0.04–0.11)</td>
<td>0.42</td>
</tr>
<tr>
<td>Procalcitonin cut-off level (number (%))</td>
<td>17 (94)</td>
<td>16 (94)</td>
<td>1.00</td>
</tr>
<tr>
<td>&lt;0.1 µg/L</td>
<td>17 (94)</td>
<td>16 (94)</td>
<td></td>
</tr>
<tr>
<td>0.1–0.25 µg/L</td>
<td>1 (6)</td>
<td>1 (6)</td>
<td></td>
</tr>
<tr>
<td>&gt;0.25 µg/L</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

To identify variables that were different by treatment group, t tests in case of normally distributed variables were performed. For not normally distributed variables this was performed by Mann-Whitney U test. Between-group comparisons of categorical variables were performed by χ² tests or Fisher’s Exact tests as appropriate.

*Baseline lung function was an earlier in stable state performed lung function measurement.
†Score according to the Stockley protocol with the nine-point colour chart (Bronko Test, Heredilab Inc, Salt Lake City, Utah, USA).
AECOPD, acute exacerbations chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in 1 s; VC, vital capacity.

---

**Figure 1** CONSORT flow chart diagram.

---

0.54 to 2.32; p=0.77) compared to the placebo group (figure 2).

Table 3 shows that there were no differences in any of the other treatment effects between the groups.

### Additional analyses

Seventy-nine per cent and 82% of the patients in the intervention and placebo group, respectively, thought they had received placebo.

At inclusion the treating physician of each patient was asked what would have been prescribed had the patient not participated in the trial. In 34% of patients, the physician would have treated the patient with prednisolone only and in 66%, with both prednisolone and antibiotics.

### DISCUSSION

This randomised, placebo-controlled trial demonstrated no difference in time taken for the resolution of AECOPDs in outpatients treated with either amoxicillin/clavulonic acid or placebo in addition to prednisolone. Also no difference in severity, number of relapses, number of AECOPDs 4 months after the study or HRQoL was observed. These conclusions apply only to patients with one or two of the following characteristics:

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Treatment effects in the two groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Amoxicillin/clavulanic acid (N=18)</td>
</tr>
<tr>
<td>Resolution of AECOPD within 28 days (number (%))</td>
<td>15 (83)</td>
</tr>
<tr>
<td>Daily AECOPD severity score (median (range))</td>
<td>5.7 (4.3–7.8)</td>
</tr>
<tr>
<td>Number of AECOPD days with a severity score ≥6 (median (range))</td>
<td>3 (0–25)</td>
</tr>
<tr>
<td>Relapse within 28 days (Number (%))</td>
<td>2 (11)</td>
</tr>
<tr>
<td>Number of AECOPDs within 4 months after end of study (number (%))</td>
<td>7 (39)</td>
</tr>
<tr>
<td>Change in CCQ scores from inclusion to day 28 (mean (SD))</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>−2.3 (2.7)</td>
</tr>
<tr>
<td>Mental state</td>
<td>−0.6 (1.5)</td>
</tr>
<tr>
<td>Functional state</td>
<td>−0.6 (1.0)</td>
</tr>
<tr>
<td>Symptom</td>
<td>−1.2 (1.4)</td>
</tr>
<tr>
<td>Change in CRQ scores from inclusion to day 28 (mean (SD))</td>
<td></td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>0.5 (1.3)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>1.2 (1.2)</td>
</tr>
<tr>
<td>Emotional function</td>
<td>0.1 (0.9)</td>
</tr>
<tr>
<td>Mastery</td>
<td>0.3 (1.4)</td>
</tr>
<tr>
<td>Change in lung function postbronchodilation from inclusion to day 28 (mean (SD))</td>
<td></td>
</tr>
<tr>
<td>FEV1 in litres</td>
<td>0.02 (0.21)</td>
</tr>
<tr>
<td>FEV1% predicted</td>
<td>1.6 (8.8)</td>
</tr>
<tr>
<td>Change in sputum colour from inclusion to day 28 (mean (SD))*</td>
<td></td>
</tr>
<tr>
<td>Mucoid to mucoid</td>
<td>1 (6)</td>
</tr>
<tr>
<td>Mucoid to purulent</td>
<td>0</td>
</tr>
<tr>
<td>Purulent to purulent</td>
<td>11 (61)</td>
</tr>
<tr>
<td>Purulent to mucoid</td>
<td>6 (33)</td>
</tr>
<tr>
<td>Procalcitonin level (µg/L) (median (range))</td>
<td>0.06 (0.03–0.26)</td>
</tr>
<tr>
<td>Procalcitonin cut-off level (number (%))</td>
<td></td>
</tr>
<tr>
<td>&lt;0.1 µg/L</td>
<td>15 (83)</td>
</tr>
<tr>
<td>0.1–0.25 µg/L</td>
<td>2 (11)</td>
</tr>
<tr>
<td>&gt;0.25 µg/L</td>
<td>1 (6)</td>
</tr>
</tbody>
</table>

To identify treatment effects that differed between the treatment groups, t tests in case of normally distributed variables were performed. For not normally distributed variables this was performed by Mann-Whitney U test. Between-group comparisons of categorical variables were performed by χ² tests or Fisher’s Exact tests as appropriate.

*Score according to the Stockley protocol with the nine-point colour chart (BronkoTest, Heredilab Inc, Salt Lake City, Utah, USA). AECOPD, acute Exacerbation in COPD; CCQ, Clinical COPD Questionnaire; CRQ, Chronic Respiratory Questionnaire.
A remarkable antibiotic probably could be justified in type II AECOPDs and that treatment of type II AECOPDs with antibiotics confer no benefit in both steroid and non-steroid users, but no data are provided. We believe that room for improvement by antibiotics will generally be less in patients treated with prednisolone, certainly in those with less severe AECOPDs.

Besides the type of Anthonisen AECOPD, we also measured PCT since this has been shown to be a marker of systemic bacterial infection. In the study of Stolz et al., PCT was also elevated at hospitalisation for AECOPD. One study suggested that PCT can be used as criterion for decisions on whether to start antibiotics. However, this could not be reproduced in another study. In our study, in which instead of hospitalised AECOPD patients, outpatients with an AECOPD were included, we observed that 20 (57%) of our patients with an AECOPD experienced a bacterial infection but that only 2 (6%) had a PCT level between 0.1 and 0.25 µg/L, which indicates possible bacterial infection. None of the patients had a PCT level >0.25 µg/L which suggests the presence of bacterial infection. Therefore, our results suggest that PCT is not an informative biomarker as a criterion for decisions on whether to start antibiotics in outpatient AECOPD with an intermediate probability of infection.

In this study we observed that even though 57% of the patients experienced a bacterial infection, antibiotics had no added value in these patients. Although this suggests refraining from administering antibiotics in outpatient AECOPDs, this inference should not be generalised from our data to all outpatients, since our patients were selected for not having a high probability of bacterial infection. We believe, however, that our results merit a supplementary randomised, placebo-controlled trial in patients with a high probability of an AECOPD of bacterial origin.

In our additional analyses, we observed that the large majority of patients on antibiotics thought they had received placebo (79%) which was very similar to the percentage in the group that really received placebo (79%). This suggests that the patients were not aware of any effect that could be caused by the antibiotics.

An important limitation of this study is the number of patients included. Based on our power calculation, we needed to include 58 patients to be able to detect a difference of 3 days in AECOPD duration between the treatment groups. We were able to include only 35 patients within the time allotted. The majority of patients were not eligible due to their participation in the COPE II study, an AECOPD or use of antibiotics or prednisolone 4 weeks prior to enrolment or their inability to produce a spontaneous sputum sample. However, with the observed HR of 1.12 and the median time to resolution of 10 days in the control group, the required sample size

Figure 2 Kaplan-Meier graph showing time to resolution for both treatment groups.

a positive Gram’s stain of sputum, a clinically relevant lung function decrease, and two or more AECOPDs in the previous year.

As detailed in the introduction, there is a paucity of good placebo-controlled studies on the effect of antibiotics in AECOPDs in addition to the treatment with systemic steroids.

Though there are large differences in prescription routines between and within countries, many physicians tend to err on the ‘safe’ side and therefore, also give antibiotics. In the current trial too we observed that 66% of the patients would have been treated with antibiotics by their physician. This routine has implications for costs, adverse effects and for the surge in antibiotic resistance especially. Therefore, evidence needs to be established also in the group with less severe AECOPDs.

Anthonisen et al performed post hoc analyses stating that type I AECOPDs were likely to be bacterial and have a more favourable outcome with antibiotics. They stated that antibiotics confer no benefit in type III AECOPDs and that treatment of type II AECOPDs with antibiotics probably could be justified in case of antibiotic tolerance. A remarkable finding in our study was that a bacterial infection was present in only 15 (56%) of the 27 type I AECOPDS. Additionally, although 15 (89%) and 12 (71%) of the AECOPDs in the amoxicillin/clavulanic acid and the placebo group, respectively, were type I Anthonisen, no effect from antibiotics was observed. These results give food for thought about the effectiveness of antibiotics in this type of AECOPD. The main difference between the study by Anthonisen and ours is the concomitant use of prednisolone, which is the standard recommendation nowadays. In the Anthonisen study only 42% received systemic steroids. The authors state that the success rate with antibiotics was favourable in both steroid and non-steroid users, but no data are provided. We believe that room for improvement by antibiotics will generally be less in patients treated with prednisolone, certainly in those with less severe AECOPDs.
would be 2450 patients. With this enormous number of patients we might have found a significant difference, but we suggest that this difference would not be clinically relevant. We, therefore, feel that the lack of effect of antibiotics is not completely based on not including 58 patients. We should, however, realise that due to the smaller number of patients included, the probability of a type II error – not rejecting the null hypothesis in case of a difference between arms – in this study will be higher than the 20% based on the power of 80%.

CONCLUSION
In conclusion, this underpowered, randomised, placebo-controlled study observed no added value of treatment with antibiotics in outpatients with moderate to severe AECOPD and intermediate probability of infection. Instead of more equivalence trials comparing two antibiotics, we need more placebo-controlled studies to determine whether we can properly define subgroups of COPD outpatients in which antibiotics indeed are of additional value and in whom there is no use at all.

Acknowledgements The authors thank the Research Department of Thermofisher, Hennigsdorf, Berlin, for supplying the PCT kits and the use of the Kryptor.

Contributors MB-K participated in designing the study, data-collection and data management, analyses and interpretation of data and writing the article. PVvdV participated in designing the study, patient inclusion, providing a clinical perspective and critically revising the article. RH participated in designing the study, providing a methodological perspective and critically revising the article. JvdP participated in designing the study, supporting data analyses, providing a methodological perspective and critically revising the article.

Competing interests None.

Patient consent Obtained.

Ethics approval Ethics committee of Medisch Spectrum Twente.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The data in the current manuscript were part of the thesis of MB-K (http://doc.utwente.nl/61073/1/thesis_M_Brusse_Keizer.pdf).

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES